Mild hypomagnesemia as the most common cisplatin nephropathy in Iran

Iranian Journal of Kidney Diseases

Volumn 7, Issue 1, 2013, Pages 23-27

  Mashhadi, Mohammad Ali ^a   Heidari, Zahra ^a   Zakeri, Zahra ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse events; Cisplatin; Hypomagnesaemia; Nephrotoxicity

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CREATININE; MAGNESIUM; UREA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CISPLATIN NEPHROPATHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; HYPOMAGNESEMIA; IRAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROECTODERM TUMOR; NEUROTOXICITY; POPULATION RESEARCH; SARCOMA; STOMACH CANCER; TASTE DISORDER; TINNITUS; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; UTERINE CERVIX CANCER; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CISPLATIN; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOCALCEMIA; IRAN; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RENAL TUBULAR TRANSPORT, INBORN ERRORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872807167     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatinassociated nephrotoxicity and pathological events. Contrib Nephrol. 2005;148:107-21.
2. Razzaque MS, Ahsan N, Taguchi T. Role of apoptosis in fibrogenesis. Nephron. 2002;90:365-72.
3. Razzaque MS. Cisplatin nephropathy: is cytotoxicity avoidable? Nephrol Dial Transplant. 2007;22:2112-6.
4. Mashhadi MA. Renal side effect of ifosfamide in patients admitted for chemotherapy. J Res Med Sci. 2008;13:240-3.
5. Mashhadi MA. The effect of high dose methotrexate in patients with neoplastic disease. Iran Red Crescent Med J. 2008;10:75-8.
6. Mashhadi MA, Sanadgol H, Keikhaei M. Ifosfamide nephropathy in patients with sarcoma. Iran J Kidney Dis. 2011;5:238-41.
7. Mashhadi MA, Mohammadi M, Bakhshipour AR, Kaykhaei MA, Hedari Z, Sandoughi M. High dose methotrexatliver toxicity. Int J Hematol Oncol Stem Cell Res. 2011;1:16-22.
8. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-20.
9. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93-130.
10. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-4.
11. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-79.
12. Litterst CL, Torres IJ, Guarino AM. Plasma levels and organ distribution of platinumin therat, dog, anddogfishfol-DDP [II]. In: A. Khan, editor. Third International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy, Dallas: Wadley Institute of Molecular Medicine; 1976. p. 169-77.
13. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994-1007.
14. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23-43.
15. Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat. 2004;7:227-32.
16. Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res. 2002;112:263-84.
17. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-4.
18. Gomez Campdera FJ, Gonzalez P, Carrillo A, Estelles MC, Rengel M. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure. Int J Pediatr Nephrol. 1986;7:151-2.
19. Hadjzadeh MA, Keshavarzi Z, Tabatabaee Yazdi SA, Ghasem Shirazi M, Rajaei Z, Khajavi Rad A. Effect of alcoholic extract of Nigella sativa on cisplatin-induced toxicity in rat. Iran J Kidney Dis. 2012;6:99-104.
20. Arunkumar PA, Viswanatha GL, Radheshyam N, Mukund H, Belliayappa MS. Science behind Cisplatin nephrotoxicity in Humans: a clnical study. Asia Pacific J Tropical Biomed. 2012;1:1-3.
21. Kazem A, Mehdi ST, Marjaneh M. Evaluation of intravenous magnesium supplementation prophylaxis for cisplatin induced hypomagnesemia. Middle East J Cancer. 2010;1:109-14.
22. Zekri J, Cheah NL, Evans L, Hancock B. Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas. J R Coll Physicians Edinb. 2009;39:301-6.
23. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer. 1998;77:1677-82.
24. Nortier J, Sculier JP. Thoracic malignancies, cisplatin and renal function. Eur Respir J. 2011;37:760-1.
25. Santoso JT, Lucci JA, 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52:13-8.
26. Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol. 2006;7:10.
27. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988;108:21-5.
28. Rivkees SA. Differentiating appropriate antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion and cerebral salt wasting: the common, uncommon, and misnamed. Curr Opin Pediatr. 2008;20:448-52.
29. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A. Cisplatin-induced renal salt wasting syndrome. South Med J. 2010;103:793-9.
30. National Cancer Institute. Cancer therapy evaluation program: common terminology criteria for adverse events version 3.0 [cited 12 December 2012]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/docs/ctcaev3.pdf
31. Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48:140-7.